Rezolute, Inc.
RZLT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RZLT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RZLT
Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and rare diseases, with its lead candidate ersodetug in Phase 3 trials for congenital hyperinsulinism.
Key risk: No revenue and accumulated losses
BioSniper Score
Based on 6 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 1 pipeline candidate · 5 clinical trials · 2 catalysts for Rezolute, Inc..
Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and rare diseases, with its lead candidate ersodetug in Phase 3 trials for congenital hyperinsulinism.
- Rezolute is a clinical-stage company with no meaningful revenue to date; its primary liquidity source has been equity financings [sec_mda · as of 2026-05-12].
- As of March 31, 2026, the company reported cash, cash equivalents, and short-term investments in marketable debt securities totaling $120.2 million [sec_mda · as of 2026-05-12].
- Net losses since inception amount to $461.0 million, and the company expects to continue incurring operating losses until regulatory approval and commercialization of a product candidate [sec_mda · as of 2026-05-12].
- Lead candidate ersodetug is being evaluated in two Phase 3 trials, with topline data expected in September and November 2027 [catalyst].
- Rezolute has milestone payment obligations of up to $25.0 million under the ActiveSite License Agreement for clinical and regulatory milestones, plus royalties of 2.0% on net sales [sec_mda · as of 2026-05-12].
What works
- Rezolute has a cash runway of $120.2 million as of March 31, 2026, which management believes is adequate to fund operations for at least 12 months [sec_mda · as of 2026-05-12].
- The company has two Phase 3 trials underway for ersodetug in congenital hyperinsulinism, a rare disease with high unmet need, and topline data are expected in late 2027 [catalyst].
- Rezolute has successfully raised capital through equity financings, receiving net proceeds of $107.0 million in fiscal 2025 and $62.6 million in fiscal 2024 [sec_mda · as of 2025-09-17].
What to weigh
- Rezolute has never generated meaningful revenue and has accumulated net losses of $461.0 million since inception [sec_mda · as of 2026-05-12].
- The company faces significant milestone payment obligations of up to $25.0 million under the ActiveSite License Agreement, with no guarantee of future revenue to cover them [sec_mda · as of 2026-05-12].
- As a clinical-stage company, Rezolute is dependent on the success of its lead candidate ersodetug, and any clinical or regulatory setback could materially impact its financial position [sec_mda · as of 2026-05-12].
- R&D expenses decreased by $3.9 million (25%) in the three months ended March 31, 2026 compared to the same period in 2025, reflecting a reduction in program spending [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
The company has incurred net losses of $461.0 million since inception and has no meaningful revenue.
“net losses of $461.0 million since our inception and as a clinical stage company we have not generated any meaningful revenue to date.”
SEC MD&A · May 12, 2026
Cash and investments totaled $120.2 million as of March 31, 2026.
“cash, cash equivalents and short-term investments in marketable debt securities totaling $120.2 million as of March 31, 2026.”
SEC MD&A · May 12, 2026
The next milestone payment of $5.0 million is due upon dosing the first patient in a Phase 3 clinical trial.
“The next milestone payment of $5.0 million will be due upon dosing of the first patient in a Phase 3 clinical trial.”
SEC MD&A · May 12, 2026
Rezolute expects to incur operating losses until regulatory approval and commercialization.
“We do not expect to generate revenue from any of our product candidates until we obtain regulatory approval and commercialize our approved product candidates.”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2027-09-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Co — Topline data from the single-arm pivotal study of ersodetug in congenital hyperinsulinism will be reported.
- 2027-11-14 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy — Topline data from the randomized, placebo-controlled Phase 3 study of ersodetug will be reported.
Risks & what to watch (4)›
Key risks
- No revenue and accumulated losses — Net losses of $461.0 million since inception; no meaningful revenue to date [sec_mda · as of 2026-05-12].
- Dependence on single lead candidate — Company is focusing resources on ersodetug; failure in Phase 3 would be material [sec_mda · as of 2026-05-12].
- Significant milestone payment obligations — Up to $25.0 million in clinical/regulatory milestones under ActiveSite agreement [sec_mda · as of 2026-05-12].
- Cash burn and financing risk — R&D expenses of $11.4 million in Q3 2026; future capital needs uncertain [sec_mda · as of 2026-05-12].
What to watch
- Phase 3 topline data for ersodetug in congenital hyperinsulinism expected in September and November 2027 [catalyst].
- Cash runway and any additional equity or debt financings to support operations beyond 12 months [sec_mda · as of 2026-05-12].
- Progress on milestone payments under the ActiveSite License Agreement, particularly the $5.0 million payment due upon Phase 3 first patient dosing [sec_mda · as of 2026-05-12].
- Regulatory updates from the FDA or other health authorities regarding ersodetug's development path [sec_mda · as of 2026-05-12].
Sources: Catalysts · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Rezolute, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rezolute, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.07 · 0% dilution
Lead: Phase 3
1 candidate
2 upcoming, next in ~367d
1 buy · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
125
Total value held
$251.9M
| Holder | Shares | Value |
|---|---|---|
| federated hermes, inc. | 12,990,659 | $39.6M |
| ra capital management, l.p. | 9,180,000 | $28.0M |
| vanguard capital management llc | 7,044,160 | $21.5M |
| blackrock, inc. | 6,313,503 | $19.3M |
| balyasny asset management l.p. | 5,048,421 | $15.4M |
| jennison associates llc | 3,438,881 | $10.5M |
| vanguard portfolio management llc | 2,981,765 | $9.1M |
| bank of america corp /de/ | 2,970,549 | $9.1M |
| morgan stanley | 2,747,671 | $8.4M |
| integral health asset management, llc | 2,000,000 | $6.1M |
Showing top 10 of 125 institutional holders of Rezolute, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 21.7%
- Days to cover
- 9.1
- Shares short
- 13,725,344
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RZLT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rezolute, Inc.?
Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and rare diseases, with its lead candidate ersodetug in Phase 3 trials for congenital hyperinsulinism.
What is Rezolute, Inc.'s lead drug candidate?
Rezolute, Inc.'s most advanced tracked candidate is ersodetug (Phase 3) for Tumor Hyperinsulinism (Tumor HI).
What is Rezolute, Inc.'s next catalyst?
Rezolute, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Co" — expected September 1, 2027.
Who is the CEO of Rezolute, Inc.?
Mr. Nevan Charles Elam J.D. is the chief executive officer of Rezolute, Inc. (RZLT).
Where is Rezolute, Inc. headquartered?
Rezolute, Inc. (RZLT) is headquartered in Redwood City, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.